JPRN-UMIN000000860已完成未知
An Open-Label, Randomized, Multicenter Study to Evaluate the Additive Effects of Montelukast and/or Salmeterol on Asthma Control Levels in Patients with Poorly Controlled Asthma Treated with Moderate doses of Inhaled Corticosteroid - Tokyo Respiratory Eminent Study for Clinical Unmet Effectiveness Study (To Rescue)
The University of Tokyo, Graduate School of Medicine, Department of Respiratory Medicine0 个研究点目标入组 100 人开始时间: 2007年10月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with COPD
研究者
相似试验
进行中（未招募）
不适用
An Open Label Study of Levetiracetam Monotherapy in Japanese Patients With Newly Diagnosed Focal EpilepsyFocal EpilepsyMedDRA version: 18.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-004377-16-Outside-EU/EEACB Japan Co. Ltd.70
已完成
不适用
A Randomized, Open-Label, Multicenter study to evaluate effect of tadalafil on lower urinary tract symptoms in patients with prostate cancer treated after radiotherapy (T-addon-RT trial)Prostate cancer treated after radiotherapyJPRN-UMIN000020674Hirosaki University Graduate School of Medicine100
进行中（未招募）
不适用
evetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial EpilepsyEpilepsyEUCTR2014-002713-32-Outside-EU/EEAKorea UCB Co. Ltd.352
招募中
3 期
A clinical trial to study the effects of two drugs Peg G-CSF and Grafeel® in the prevention of reduction in neutrophil counts in cancer patients caused by drugs used to treat cancer.CTRI/2009/091/000694DR.REDDY'S LABORATORIES LTD.Biologics Development Centre , Survey No.47, Bachupalli, Qutubullapur, Hyderabad-500090, A.P, IndiaFax: +91-40-44644507, 91-40-23041418150
进行中（未招募）
不适用
An open-label, randomized, multicenter study to evaluate the use of Zoledronic Acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapy - ZoFast2406Prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapyEUCTR2004-001369-17-ESovartis Farmacéutica S.A.400